Vivani Medical (NASDAQ:VANI) Stock Price Down 2.6% – Should You Sell?

Shares of Vivani Medical, Inc. (NASDAQ:VANI) were down 2.6% during trading on Wednesday . The company traded as low as $1.14 and last traded at $1.14. Approximately 200,438 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 206,206 shares. The stock had previously closed at $1.17.

Analyst Upgrades and Downgrades

VANI has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. Wall Street Zen upgraded Vivani Medical to a “sell” rating in a research report on Saturday, November 22nd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $4.00.

Vivani Medical Stock Performance

The stock’s fifty day moving average is $1.28 and its two-hundred day moving average is $1.36. The firm has a market cap of $85.99 million, a price-to-earnings ratio of -2.44 and a beta of 3.17.

Insider Transactions at Vivani Medical

In other Vivani Medical news, Director Gregg Williams bought 1,737,765 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were purchased at an average price of $1.14 per share, with a total value of $1,981,052.10. Following the purchase, the director directly owned 26,564,109 shares of the company’s stock, valued at approximately $30,283,084.26. The trade was a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders purchased 4,826,881 shares of company stock valued at $5,962,104. Corporate insiders own 46.40% of the company’s stock.

Hedge Funds Weigh In On Vivani Medical

Hedge funds have recently modified their holdings of the company. Panagora Asset Management Inc. acquired a new stake in shares of Vivani Medical in the second quarter valued at $25,000. Citadel Advisors LLC acquired a new stake in Vivani Medical in the 3rd quarter valued at about $26,000. Susquehanna International Group LLP boosted its position in shares of Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after purchasing an additional 16,200 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Vivani Medical in the 4th quarter worth approximately $60,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after purchasing an additional 53,127 shares in the last quarter. 6.78% of the stock is currently owned by institutional investors and hedge funds.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.